ALNYLAM PHARMACEUTICALS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alnylam Pharmaceuticals, Inc. on February 15, 2008, reporting an event that occurred on February 11, 2008. The filing pertains to corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
The primary material change reported is the election of a new director:
- Edward M. Scolnick, M.D. was elected as a Class III director.
- His term expires at the annual meeting of stockholders in 2010.
Compensatory Arrangements and Outlook
In connection with his election, Dr. Scolnick received the following compensation:
- A stock option grant for 45,000 shares of common stock.
- The options vest annually over three years.
- He will receive standard director compensation pursuant to the Company's policy for non-employee directors, as detailed in the 2007 Proxy Statement.
The filing contains no guidance, outlook, risk factors, or discussion of unusual items beyond the director election.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 45,000 stock options granted to Dr. Scolnick.
- Review the 2007 Proxy Statement (filed April 30, 2007) to confirm the specific cash compensation policy for non-employee directors.
- Confirm Dr. Scolnick's background and potential conflicts of interest as a new Class III director.